Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

As indicated by the release of the China Cardiovascular Health and Disease Report 2019, the current number of cardiovascular patients is 330 million and is still on the rise.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

In vitro fertilization embryos are prone to chromosomal aneuploidy abnormalities. Chromosome aneuploidy refers to the increase or decrease in the number of a single chromosome or multiple chromosomes.

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic medical device that harnesses AI to generate heatmaps identifying small and rare missed prostatic cancers, acting as a safety net that assists pathologists in ensuring patients receive an accurate diagnosis.

MRC Holland said Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR).

Imagene, a leader in AI-powered Oncology Intelligence, today announced a collaboration with Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care. The collaboration aims to advance cancer diagnostics by accelerating biomarker prediction, integrating AI-powered tools into clinical workflows, and enabling the commercialization of accessible diagnostic solutions.

Illumina, Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the fourth quarter and fiscal year 2024. The financial results for fiscal year 2024 and Q4 2023 and fiscal year 2023 include the financial results for GRAIL which was spun off on June 24, 2024.

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter ended December 31, 2024, and provided 2025 guidance.

Siemens Healthineers AG today announces its results for the first quarter of fiscal year 2025 ended December 31, 2024.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced financial results for the fourth quarter and full-year 2024.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.